1.The efficacy of oral Micronized Progesterone versus Medroxyprogesterone Acetate in the control of mild to moderate abnormal uterine bleeding - ovulatory Dysfunction (AUB-O) in adolescents: An open label randomized controlled trial
Angeline G. Santos ; Mary Carmona-Tan ; Ma. Socorro C. Bernardino
The Philippine Children’s Medical Center Journal 2023;19(2):75-86
Objectives:
To determine the efficacy of micronized oral progesterone (OMP) versus
Medroxyprogesterone Acetate (MPA) in the control and regulation of mild to moderate abnormal
uterine bleeding in adolescents with ovulatory dysfunction.
Materials and Methods
This is an open labelled Randomized Controlled Trial. Fifty
patients with mild to moderate abnormal uterine bleeding were randomized to treatment with
Medroxyprogesterone Acetate or Oral Micronized Progesterone.
Medroxyprogesterone Acetate
2.Oral medroxyprogesterone acetate: a review of its clinical uses in adolescents
De Guia Blanca C. ; Dobles-Dizon Christine O.
Philippine Journal of Reproductive Endocrinology and Infertility 2005;2(2):57-59
Although oral medroxyprogesterone acetate has been used in various gynecologic conditions in women, literature is scant on its use in adolescents. Hence, this article reviews the clinical indications of oral medroxyprogesterone in these young women.
MEDROXYPROGESTERONE ACETATE
;
PROGESTINS
3.Marked Regression of Bilateral Pulmonary Metastases: Report of A Case Renal Cell Carcinoma after Nephrectomy and Medroxyprogesterone Acetate Therapy.
Kwang Jin KIM ; Sung Seok HAN ; Jin Moo LEE
Korean Journal of Urology 1986;27(2):283-286
A case of marked regression of bilateral pulmonry metastases is presented. The pulmonary metastases were confirmed histologically by ultrathin needle aspiration cytology before radical nephrectomy. Demonstrable regression was noticed 2 months after hormonal therapy with medroxyprogeaterone acetate following nephrectomy. Attention is drawn to the use of hormonal therapy in the treatment of advanced renal cell carcinoma.
Carcinoma, Renal Cell*
;
Medroxyprogesterone Acetate*
;
Medroxyprogesterone*
;
Needles
;
Neoplasm Metastasis*
;
Nephrectomy*
4.In vitro respones of gynecological cancer cell lines to the GnRH agonist, medroxyprogesterone acetate and tamoxifen.
Jong Woo SOHN ; Jai Kyung PRK ; Seon Kyung LEE ; Seung Bo KIM ; Bo Hoon OH
Korean Journal of Obstetrics and Gynecology 1993;36(9):3436-3443
No abstract available.
Cell Line*
;
Gonadotropin-Releasing Hormone*
;
Medroxyprogesterone Acetate*
;
Medroxyprogesterone*
;
Tamoxifen*
5.The Women’s Health Initiative after 17 years: Has it done more harm than good?
Delfin A. Tan ; Gladys Anne M. Bermio
Philippine Journal of Obstetrics and Gynecology 2019;43(4):34-38
This commentary is focused primarily on the relationship between menopausal hormone therapy (MHT) and breast cancer risk, the primary adverse outcome measure of the Women’s Health Initiative (WHI) hormone trials. The WHI hormone trials are to date the largest randomized, placebo-controlled studies that evaluated the risks and benefits of hormone therapy in postmenopausal women. There are two arms: the estrogen-progestin (conjugated equine estrogen/medroxyprogesterone acetate) arm for women with intact uterus and the estrogen-alone (conjugated equine estrogen) arm for women who had a hysterectomy1. Both arms, planned to continue for 8.5 years, were stopped prematurely, the CEE/MPA arm after a mean of 5.2 years of follow-up and the CEE-alone arm after a mean of 7.2 years follow-up.
Female
;
Estrogens, Conjugated (USP)
;
Medroxyprogesterone Acetate
6.Changes in Endometrial Thickness in Postmenopausal Women During Hormone Replacement Therapy.
Young Min CHOI ; Eun Kyong KIM ; Seung Yup KU ; Chang Suk SUH ; Seok Hyun KIM ; Jung Gu KIM ; Shin Yong MOON ; Yong Hee LEE ; Jin Yong LEE
Korean Journal of Obstetrics and Gynecology 2000;43(4):682-687
OBJECTIVE: The purpose of this study was to evaluate the effect of hormone replacement therapy on endometrial thickness in postmenopausal women and to assess the difference in endometrial thickness by the type of hormone replacement therapy (HRT). MATERIALS AND METHODS: Endometrial thickness was measured in 258 postmenopausal women before and/or during 12 months of HRT. The subjects were grouped into the sequential therapy group (Group 1, 72 women) and continuous combined therapy group (Group 2, 186 women). Group 1 received 0.625 mg of conjugate equine estrogen (CEE) daily with cyclic addition of medroxyprogesterone acetate (MPA, 10 mg/day for 12 days per month). Group 2 received 0.625 mg of CEE with daily addition of MPA (2.5 mg/day). RESULTS: The sequential group showed no significant change in endometrial thickness during HRT compared to that before HRT. However, a significant increase in endometrial thickness was found in the continuous combined group at 12 months of treatment. Before HRT, the endometrial thickness in the continuous combined group was thinner than that of the sequential group. During 12 months of treatment, there was no difference in endometrial thickness between the types of HRT. And the proportion of patients with endometrial thickness of 8mm or greater at 12 months of treatment did not differ significantly from that before treatment in both groups. CONCLUSION: Sequential HRT did not influence the endometrial thickness during treatment. However, continuous combined HRT increased the endometrial thickness during 12 months of treatment compared to that before treatment. The different endometrial responses to each HRT regimen may be due to the difference in endometrial thickness before treatment in each group.
Estrogens
;
Female
;
Hormone Replacement Therapy*
;
Humans
;
Medroxyprogesterone Acetate
7.Biodehydrogenation of 11beta-hydroxyl melroxyprogesterone by Arthrobacter simplex UR016 in microemulsion system.
Yufen YANG ; Pu WANG ; Junyao HE ; Songlin XIE
Chinese Journal of Biotechnology 2009;25(6):892-896
To improve mass transfer and enhance the yield for C(1,2) biodehydrogenation of steroid 11beta-hydroxyl medroxyprogesterone, we carried out the dehydrogenation reaction of 11beta-hydroxyl medroxyprogesterone in an oil-in-water (O/W) microemulsion by Arthrobacter simplex UR016. We studied the effects of system composition, dehydrogenation temperature and substrate concentration on microbial transformation. We formulated a suitable O/W microemulsion system with Arthrobacter simplex UR016 culture broth as aqueous phase, 10 g/L of edible oil as oil phase, 4 g/L of Tween-O80 and 7% (V/V) alcohol as surfactant and cosurfactant. The optimal dehydrogenation temperature was 33 degrees C. The results showed that in Tween-80/alcohol/edible oil/water microemulsion system, the hydrophobic steroid was solubilised and diffused effectively, with the maximum conversion rate of 88.6% at 46 h under 4 g/L substrate concentration, an increase of 66.2% compared to that in aqueous system. The C(1,2) biodehydrogenation of 11beta-hydroxyl medroxyprogesterone is more efficient in water-edible oil microemulsion system than in aqueous system.
Arthrobacter
;
metabolism
;
Biotransformation
;
Emulsions
;
Hydrogenation
;
Medroxyprogesterone
;
chemistry
;
metabolism
8.Early Experience of Combination Therapy with Chemo-Immuno-Hormonal Agents in Advanced Renal Cell Carcinoma.
Dong Hyeon LEE ; Sung Joon HONG ; Byung Ha CHUNG ; Dong Won PARK
Korean Journal of Urology 1996;37(6):639-645
Surgical tumor resection, most appropriately together with the affected organ, is the sole form of curative therapy in low-staged renal cell carcinoma. But the fact that about 30% of patients show distant metastases or regional lymph node metastases at the time of diagnosis of renal cell carcinoma indicates the urgent need for the development of an effective treatment modalities. Herein we report the preliminary result of chemo-immuno-hormonal(triple) combination therapy which consists of a-interferon, vinblastine and medroxyprogesterone acetate in 17 patients with metastatic renal cell carcinoma from June 1990 to June 1994. The patients received the treatment with the combination of alpha interferon(a-IFN: 6 million units IM three times a week), vinblastine(VBL: 3 mgN2 IV monthly) and medroxyprogesterone acetate(MPA: 600 mg IM twice a month) at least 6 cycles. Although almost all the patients tolerated the treatment a few patients were stopped the treatment when the general condition of the patient became poor in progressive disease The 5 of 17 patients showed partial response and one patient with lung and liver metastasis was resolved completely. The response rate was 35.3% after treatment and the survival rates for 6 month and 1 year were 70.6% and 47.1%, respectively. So the chemo-immuno-hormonal combination therapymight be an alternative safe modality and be able to prolong the survival duration in patients with advanced renal cell carcinoma.
Carcinoma, Renal Cell*
;
Diagnosis
;
Drug Therapy
;
Humans
;
Liver
;
Lung
;
Lymph Nodes
;
Medroxyprogesterone
;
Medroxyprogesterone Acetate
;
Neoplasm Metastasis
;
Survival Rate
;
Vinblastine
9.Treatment of endometrial hyperplasia with Medroxyprogesterone acetate(MPA).
Seok Mo KIM ; Kwang Sik SHIN ; Yoon Ha KIM ; Ho Sun CHOI ; Ji Soo BYUN
Korean Journal of Obstetrics and Gynecology 1999;42(8):1655-1660
OBJECTIVE: To investigate the response of hyperplastic endometrium to Medroxyprogesterone acetate according to the histologic types such as simple typical, complex typical and atypical hyperplasia. METHODS: A total of 79 patients with histologically proved endometrial hyperplasia were enrolled into this prospective study between March 1996 and May 1998. Patients without atypia were placed on a regimen of cyclic therapy with 10mg MPA orally, each day for 14days per month for 3 months. In the cases in which hyperplasia did not regress , MPA was increased to 20mg. Patients with atypical hyperplasia received continuous MPA therapy, 20mg orally each day for 3 month. All patients were followed up for a minimum of 3 months and a maximum of 1 year(mean 7 months). RESULTS: In patients with simple typical hyperplasia, 45 patients(80.4%) had regression, 11 patients(19.6%) had persistence and none had progression. In patients with complex typical hyperplasia, 10 patients(83.3%) had regression, 2 patients(16.7%) had persistence and none had progression. But, in patients with atypical hyperplasia 5 patients(45.4%) had regression, 4 patients(36.4%) had persistence and 2(18.2%) patients had well differentiated endometrial adenocarcinoma. There was no recurrence during the follow up. CONCLUSION: This data suggest that most women with typical hyperplasia respond to progestin therapy, but there is high failure rate of response to progestin therapy and risk of endometrial cancer in patients with atypical hyperplasia. If the young patient desires to preserve her fertility, then progestin therapy may be considered as primary treatment in patients with atypical hyperplasia. But older patients in whom fertility is not an issue, hysterectomy should be selected as treatment of choice for atypical lesion.
Adenocarcinoma
;
Endometrial Hyperplasia*
;
Endometrial Neoplasms
;
Endometrium
;
Female
;
Fertility
;
Follow-Up Studies
;
Humans
;
Hyperplasia
;
Hysterectomy
;
Medroxyprogesterone Acetate
;
Medroxyprogesterone*
;
Prospective Studies
;
Recurrence
10.The Effect of Medroxyprogesterone Acetate On Cytotoxicity of Vinblastine in Renal Cell Carcinoma Cell Lines.
Dong Hyeon LEE ; Byung Ha CHUNG ; Sung Joon HONG
Korean Journal of Urology 1997;38(1):1-6
Inadequate effectiveness of anticancer drug in treating renal cell carcinoma has been attributed to the overexpression of multidrug resistance gene (MDR1) and its product, membrane-bound P-glycoprotein. P-glycoprotein is known to actively pump out intracellular drug, which results in low intracellular anticancer drug concentration. Progesterone, which has been used in patients with advanced renal cell carcinoma is found to cause a three to four-fold increase in vinblastine accumulation in the P-glycoprotein-expressing murine macrophage-like cell line.We have studied to evaluate the MDR modulating action of medroxyprogesterone acetate (MPA) in renal cell carcinoma cell lines also with tamoxifen and verapamil. A-498 of a high mdrl expressed cell line and Caki-2 of a low mdrl expressed cell line were each placed in 96 multiwell plates. Vinblastine, in concentration from 0.01 ug/ml to 10 ug/ml was added to each well and verapamil, from 0.1 uM to 10 uM, MPA, from 2.5 uM to 25 uM, or tamoxifen, from 0.1 uM to 10 uM was also added. The in vitro chemosensitivity of two renal cell carcinoma cell lines (Caki-2 and A498) to vinblastine was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazol bromide(MTF) colorimetric assay. Growth of Caki-2 cells is inhibited by low doses of vinblastine(IC50: 0.27 ug/ml), but A-498 cells are highly resistant to the drug, with ICs0 value of 0.47 ug/ml. The chemosensitivity of the A-498 cells is increased in response to 5 uM MPA, 1 uM verapamil and 2 uM tamoxifen, which are known to partially reverse the MDR phenotype in other resistant tumors. The effective concentration of MPA for MDR reversal is in clinically achievable concentration but one of verapamil is not. The chemosensitivity of Caki-2 cells does not change according to MDR modulating agents. .MPA is an effective MDR modulating agents to enhance the cytotoxicity of vinblastine in renal cell carcinoma cell line showing P-glycoprotein expression. It suggests that combination therapy of MPA and vinblastine is better than monotherapy with MPA or vinblastine alone.
Carcinoma, Renal Cell*
;
Cell Line*
;
Drug Resistance, Multiple
;
Genes, MDR
;
Humans
;
Medroxyprogesterone Acetate*
;
Medroxyprogesterone*
;
P-Glycoprotein
;
Phenotype
;
Progesterone
;
Tamoxifen
;
Verapamil
;
Vinblastine*